Vir Biotechnology, Inc.
VIRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Vir Biotechnology, Inc. focuses on Biotechnology services and products. Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and. The $1.79B market capitalization puts VIR squarely in small-cap range for its industry. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Market Cap
$1.79B
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
-4.25
EPS (TTM)
$-1.76
EPS (Fwd)
$-2.49
ROE
-26.1%
ROA
-14.5%
Cash
$532.7M
Total Debt
$93.3M
Free CF
-$38.9M
52W Change
70.8%
Annual Financials
Cash vs Debt
Where VIR stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, VIR finished 6.84% above its 150-day moving average ($9.80) and 13.19% above its 200-day moving average ($9.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VIR overbought or oversold?
At the October 16, 2026 close, VIR's RSI(14) was 47.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $532.7M in cash comfortably exceeding the $93.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$38.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $1.58B to $66.5M.
Vir Biotechnology, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vir Biotechnology, Inc. and its sector.